Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease
- Sponsor
- Oslo University Hospital
- Study ID
- NCT02073526
- Status
- Completed
Conditions
- Crohn's Disease
- Inflammatory Bowel Disease
- Ulcerative Colitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Infliximab, adalimumab, certolizumab pegol — DRUGPatients are treated with the above mentioned drugs decided by clinicians
Study Details
Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents. The purpose is to determine which patients that will clinically benefit from either discontinue treatment, adjusting the dose, switch to another anti-TNF agent or a different class of medication.
Key Dates
- Start date
- May 31, 2013
- Status verified
- Dec 2016
- Primary completion
- May 31, 2016
- Completion
- Nov 30, 2016
Study Design
- Enrollment
- 1,230 participants (actual)
Arms
- Arm: Anti-TNFInflammatory bowel patients age 18 and over treated with anti-TNF agents
Primary Outcome Measure
Measurement of drug serum concentrations [ Time Frame: Serum samples will be collected on average 8 weeks (range 0-90 days) after drug administration ]
Related Studies
- Immune Regulation in Ulcerative Colitis or Crohn s DiseaseRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Autologous Stem Cell Transplantation for Crohn's DiseasePHASE1/PHASE2 · Recruiting · Paul Szabolcs · Pittsburgh, Pennsylvania
- A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel DiseaseRecruiting · University of California, San Francisco · San Francisco, California
- Gene Expression in Inflammatory Bowel DiseaseEnrolling By Invitation · Johns Hopkins University · Baltimore, Maryland